Business Wire

Primary endpoint met in the CLEAR Outcomes Trial of bempedoic acid showing statistically significant relative risk reduction in major adverse CV events

Share

Daiichi Sankyo Europe, (hereafter, Daiichi Sankyo) announced today that the primary endpoint was met in the Phase 3 cardiovascular CLEAR (Cholesterol Lowering via Bempedoic acid, an ATP citrate lyase (ACL)-Inhibiting Regimen) Outcomes Trial, demonstrating statistically significant relative risk reduction in major adverse CV events (MACE-4) in patients treated with 180 mg/day bempedoic acid compared to placebo (with no or very low statin background).1,3

Comprehensive data from the CLEAR Outcomes Trial, led by US-based biotech company Esperion Therapeutics Inc., will be presented at a key medical congress in early 2023 and subsequently submitted to applicable regulatory authorities. The initial findings from the data indicate that bempedoic acid is the first oral, ACL inhibitor known to reduce both LDL-C levels and risk of major adverse CV events.1 The findings are congruent with previous significant evidence and the latest clinical guidelines highlighting that the lower a person’s LDL-C level, the lower their cardiovascular risk.4

“The positive results from the CLEAR Outcomes Trial represents a pivotal step towards reducing the impact of CVD in Europe for patients who are currently at high risk of heart attack and stroke,” said Professor Kausik Ray, Professor of Public Health and President of the European Atherosclerosis Society, Honorary Consultant Cardiologist, Director ICTU Global and Deputy Director of the Imperial Clinical Trials Unit at Imperial College London. “I am very excited to see more data from the trial over the coming months and better understand how bempedoic acid can continue to help clinicians bring LDL-C levels of patients to guideline-recommended goals and thus reduce the impact of cholesterol on CV health in Europe.”

“With 10,000 lives lost everyday to CVD in Europe, we are truly encouraged by this new data, which demonstrates that bempedoic acid does reduce the risk of serious CV events for patients who are at high-risk of experiencing a heart attack or stroke,” 1,4 said Dr Stefan Seyfried, Vice President Medical Affairs Specialty Medicines, Daiichi Sankyo Europe GmbH. “We look forward to sharing additional analyses and insights, as well as working closely with the scientific and clinical communities, to better understand how the data can support their care for CVD patients across Europe.”

CLEAR Outcomes was a Phase 3, event-driven, randomised, multicenter, double-blind, placebo-controlled trial designed to evaluate whether treatment with bempedoic acid reduced the risk of CV events in patients with or who are at high risk for ASCVD with documented statin intolerance and elevated LDL-C levels (fasting blood LDL-C ≥ 100 mg/dL (2.6 mmol/L)).3 The study, which was fully enrolled in August 2019, included 14,014 patients at over 1,200 sites in 32 countries. Patients had at least 36 months of follow-up.3

-ENDS-

About bempedoic acid

Bempedoic acid (commercialised in the European Economic Area, Turkey and Switzerland as NILEMDO® ) is a first-in-class, oral treatment which lowers cholesterol, and which can be combined with other oral treatments to help lower cholesterol even further.2,5 Bempedoic acid inhibits ATP citrate lyase (ACL), an enzyme which is involved in the production of cholesterol in the liver.2

Bempedoic acid has been approved for use in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet:2

  • in combination with a statin or statin with other lipid-lowering therapies in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin, or
  • alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.

Bempedoic acid acts on the well-known cholesterol synthesis pathway, upstream of the statin target in the liver, which allows additional LDL-C lowering when added to statin or other lipid-lowering therapies. Due to its unique mechanism of action, bempedoic acid is not activated in skeletal muscle.

Daiichi Sankyo Europe has licensed exclusive commercialisation rights to bempedoic acid in the European Economic Area, Turkey and Switzerland from Esperion and is the full Marketing Authorisation Holder in these territories.

About Daiichi Sankyo

Daiichi Sankyo is dedicated to creating new modalities and innovative medicines by leveraging our world-class science and technology for our purpose “to contribute to the enrichment of quality of life around the world.” In addition to our current portfolio of medicines for cancer and cardiovascular disease, Daiichi Sankyo is primarily focused on developing novel therapies for people with cancer as well as other diseases with high unmet medical needs. With more than 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 16,000 employees around the world draw upon a rich legacy of innovation to realise our 2030 Vision to become an “Innovative Global Healthcare Company Contributing to the Sustainable Development of Society.”

For more information, please visit www.daiichisankyo.com

This medicinal product is subject to additional monitoring.

____________________________________________________

1 https://www.esperion.com/news-releases/news-release-details/esperion-announces-clear-cardiovascular-outcomes-trial-nexletolr.

2 European Medicines Agency. NILEMDO Summary of Product Characteristics. Available at: https://www.ema.europa.eu/en/documents/product-information/nilemdo-epar-product-information_en.pdf. Last accessed December 2022.

3 Nicholls, S.J., et.al. Rationale and design of the CLEAR-outcomes trial: Evaluating the effect of bempedoic acid on cardiovascular events in patients with statin intolerance. Am Heart J. 2021. 235: 104–112.

4 The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). ESC/EAS guidelines for the management of dyslipidaemia. Eur Heart J. 2020. 41(1):111–188.

5 SwissMedic. NILEMDO (bempedoic acid) Product Information for Human Medicinal Products. Available at: https://www.swissmedic.ch/swissmedic/en/home/about-us/publications/public-summary-swiss-par/public-summary-swiss-par-nilemdo.html. Last accessed December 2022.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Dr. Wolfgang Schiessl
Daiichi Sankyo Europe GmbH
PR & Portfolio Communication Lead, Specialty Medicines
+49 151 1714 7317

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Bermuda Risk Summit 2023 – 27 January Last Chance to Secure Early Bird Rate26.1.2023 20:44:00 EET | Press release

Potential attendees of the Bermuda Business Development Agency’s (BDA) second annual Bermuda Risk Summit, being held at the Hamilton Princess & Beach Club from March 6-8, are reminded the early bird registration price will end tomorrow, Friday, 27 January. Included in the early bird price are keynote breakfasts, networking breaks and lunches, an evening seaside soiree, and an island lunch cruise. Overseas guests should also act before midnight on Mon day, February 6 to secure special hotel room rates starting at $359 (plus tax). From February 7, hotel room rates will increase significantly, or be completely sold out, due to limited availability. To book your room please call 1-441-295-3000 or the Global Reservations Centre on 1-800-441-1414. Alternatively, click here to reserve your room online. Please use the booking code: ‘Bermuda Risk’ to take advantage of the preferred rate. The Bermuda Risk Summit, which has the Association of Bermuda Insurers and Reinsurers (ABIR) and EY as headl

Verimatrix Secure Delivery Platform Marks Its First Year with Billions of Video Viewership Licenses Served26.1.2023 19:45:00 EET | Press release

Regulatory News: Verimatrix, (Euronext Paris: VMX) (Paris:VMX), the leader in powering the modern connected world with people-centered security, today announced its Verimatrix Secure Delivery Platform quickly reached billions of delivered video viewership licenses in less than a year since its launch. The company also debuts key enhancements that provide even greater value to media companies, content owners, streaming media providers and operators. As a single pane of glass experience, the Verimatrix platform secures enterprises by protecting and monitoring their content, applications and devices through a streamlined cloud-based solution that brings a highly noticeable combination of cost savings and efficiency while also maximizing agility for the content delivery process. Newly released enhancements include: Full Verimatrix XTD integration, including App Shield and threat monitoring – offering unmatched visibility into potentially dangerous enterprise threat blind spots Integration

Fabasoft Takes Ambitious Climate Action Measures26.1.2023 17:00:00 EET | Press release

Fabasoft sets a bold near-term target, pledging to decrease its direct (Scope 1) and indirect CO2 emissions from purchased energy (Scope 2) by at least 42% by 2030, as compared to the base year 2021. In addition, the company aims to reduce its indirect Scope 3 emissions through the sustainable design of supply chains and employee commutes. To reach this goal, Fabasoft undertakes a number of actions, including increasing the use of renewable energies, fostering e-mobility, designing energy-efficient office spaces, and focusing on organic, regional and short distance transport routes. Subsidies for the climate ticket or the Linz city cycling initiative as well as the expansion of e-charging stations encourage employees to switch to sustainable means of transport. To complement the climate ticket, Fabasoft provides a free e-shuttle service from the train station to the headquarters in Linz and back since 2022. "We are convinced that it is our responsibility to actively address global warm

Wemade Presents New Battlefield ‘Snowfield Area’ in MIR426.1.2023 17:00:00 EET | Press release

Wemade’s blockbuster mobile MMORPG MIR4 released a new battlefield, Snowfield Area, on January 26th. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230126005414/en/ MIR4 New Battlefield ‘Snowfield Area’ opened (Graphic: Wemade) Snowfield Area is divided into 5 parts: Nine Dragon Ice Field, Nine Dragon Ice Palace, Nine Dragon Labyrinth, Sagittarion Valley, and Sagittarion Temple. Players can clear new quests in Snowfield Area and begin new adventures to find the lost Princess Cheonpa. Max. character Level has been increased to 180. The Max. level for Constitution has also been increased to 19, and Inner Force to 18. Upon reaching Lv. 180, characters will be able to obtain 'Level Reward Coffer' which contains 'Mystic Mystical Piece Summon Box', 'Epic Divine Dragon's Enhancement Stone', and more, as well as 'Legendary Blue Dragon Statue'. The first Party Leader Spirit, Small White Dragon Chunryu, has also been added. The spirit

FarEye’s Eye on Last-mile Delivery Report Finds 84% of Retailers Lack Control of their Outsourced Delivery Networks26.1.2023 17:00:00 EET | Press release

The FarEye Eye on Last-mile Delivery Report, conducted with Researchscape International, explores retailers’ and logistics providers’ last-mile delivery priorities and opportunities over the next five years. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230126005266/en/ Eye on Last-mile Delivery Report (Graphic: Business Wire) Since 2020, last-mile delivery has gone through a transformation, yielding a complex, expensive, inefficient, and unsustainable process. To reduce growing last-mile delivery costs, FarEye’s research revealed that 57% of retailers have outsourced their delivery networks over the past five years, yet 84% of retailers claim their organization needs more control over their outsourced delivery networks. In a climate where revenue growth, efficiency and sustainability are key priorities for every company, last-mile delivery strategies must adapt to balance reducing delivery costs and improving consumer expe

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom